₩14,080.00 ($10.47)

-70.00 (-0.49%)

Weekly Expected Move ±5.5%

₩12518 ₩13299 ₩14080 ₩14861 ₩15642

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 51 · ₩373.1B mcap · 18M float · 0.028% daily turnover

Analysis Technicals Weather Peers

Revenue

$234.7B +6.1% ▲

5Y CAGR: +3.5%

Gross Profit

$102.4B +25.1% ▲

5Y CAGR: +6.0%

Operating Income

$14.3B +169.7% ▲

5Y CAGR: +4.7%

Net Income

$8.8B +157.4% ▲

5Y CAGR: +12.0%

EPS (Diluted)

$149.26 +149.7% ▲

5Y CAGR: +8.5%

EBITDA

$25.6B +94595.4% ▲

5Y CAGR: +4.0%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$189.2B	$209.3B	$200.2B	$221.1B	$234.7B
YoY Growth	-4.3%	+10.6%	-4.3%	+10.4%	+6.1%
Cost of Revenue	$111.8B	$131.3B	$120.0B	$139.3B	$132.3B
Gross Profit	$77.4B	$78.0B	$80.3B	$81.8B	$102.4B
Gross Margin	40.9%	37.3%	40.1%	37.0%	43.6%
R&D Expenses	$17.3B	$30.4B	$56.0B	$17.9B	$12.3B
SG&A Expenses	$30.0B	$35.3B	$36.9B	$33.9B	$75.8B
Operating Expenses	$91.7B	$112.0B	$127.6B	$102.3B	$88.1B
Operating Income	-$9.0B	-$34.0B	-$47.4B	-$20.5B	$14.3B
Operating Margin	-4.8%	-16.3%	-23.7%	-9.3%	6.1%
Interest Expense	$202M	$61M	$1.7B	$2.6B	$2.7B
Income Before Tax	-$9.0B	-$34.8B	-$53.4B	-$14.6B	$8.5B
Tax Expense	$2.5B	$527M	$3.8B	$751M	$62M
Net Income	-$11.5B	-$35.3B	-$57.3B	-$15.4B	$8.8B
Net Margin	-6.1%	-16.9%	-28.6%	-7.0%	3.8%
EPS (Diluted)	$-224.84	$-688.79	$-1118.28	$-300.17	$149.26
EBITDA	$1.3B	-$21.9B	-$39.8B	-$27M	$25.6B
Shares Outstanding	51M	51M	51M	51M	55M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$55.8B	$55.3B	$55.4B	$58.6B	$62.6B	$58.0B	$54.5B	$63.9B
Cost of Revenue	$33.6B	$35.9B	$33.7B	$31.3B	$33.9B	$33.3B	$33.4B	$37.1B
Gross Profit	$22.2B	$19.4B	$21.7B	$27.3B	$28.7B	$24.7B	$21.1B	$26.7B
Gross Margin	39.8%	35.1%	39.1%	46.6%	45.8%	42.6%	38.7%	41.9%
R&D Expenses	$0	$5.9B	$3.8B	$5.2B	$2.4B	$2.2B	$6.5B	$4.4B
SG&A Expenses	$22.4B	$9.6B	$23.4B	$22.4B	$6.4B	$7.2B	$6.2B	$31.3B
Operating Expenses	$22.4B	$31.5B	$23.4B	$22.4B	$21.5B	$20.8B	$21.6B	$34.8B
Operating Income	-$165M	-$12.1B	-$1.8B	$4.9B	$7.2B	$3.9B	-$490M	-$8.0B
Operating Margin	-0.3%	-21.9%	-3.2%	8.4%	11.5%	6.7%	-0.9%	-12.6%
Interest Expense	$632M	$685M	$718M	$656M	$643M	$672M	$863M	$857M
Income Before Tax	$39M	-$10.0B	-$1.5B	$2.3B	$7.3B	$303M	$440M	-$8.0B
Tax Expense	$119M	$2.7B	-$203M	-$434M	$848M	-$148M	$71M	-$18M
Net Income	-$98M	-$12.6B	-$1.3B	$3.3B	$6.4B	$461M	$359M	-$8.0B
Net Margin	-0.2%	-22.9%	-2.3%	5.6%	10.2%	0.8%	0.7%	-12.5%
EPS (Diluted)	$-1.92	$-246.55	$-26.00	$61.00	$124.00	$9.00	$6.68	$-149.23
EBITDA	$3.4B	-$6.5B	$24.5B	$30.0B	$10.9B	$6.7B	$2.3B	-$5.3B
Shares Outstanding	51M	51M	49M	51M	51M	55M	54M	54M

019175.KS KSC